
NuCana Reports Q3 2025 Financial Results and Board Resignation

I'm PortAI, I can summarize articles.
NuCana announced Q3 2025 financial results, reporting reduced operating losses of £779,000, down from £5.3 million in 2024, but still facing financial challenges with a comprehensive loss of £267,000. Additionally, Dr. Bali Muralidhar resigned from the Board, effective October 21, 2025, without disagreements. Spark rates NCNA as Underperform due to financial instability and negative valuation metrics, despite strong cash management. NuCana specializes in developing novel cancer treatments.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.

